Credit Suisse Downgrades Diplomat Pharmacy (DPLO) to Underperform on Slowing Organic Growth, Profit Challenges
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Credit Suisse downgraded Diplomat Pharmacy (NYSE: DPLO) from Neutral to Underperform with a price target of $13.00 (from $18.00) on continuing growth, profitability concerns.
Analyst Robert Willoughby commented, "We are incrementally negative on DPLO's slowing organic growth and profit challenges that exacerbate our concerns over its limited value proposition to health care payors. DPLO will not grow operating income in 2017, and while acquisitions may compensate for slowing growth, its invested capital base is ballooning. The 3Q16 guidance set removes some near term risk, but our conviction in our EPS estimates is lower, and a clear pathway to higher ROIC is still not apparent."
Shares of Diplomat Pharmacy closed at $14.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- UPDATE: SunTrust Robinson Humphrey Downgrades Simon Property Group (SPG) to Hold
- Instinet (Nomura) Downgrades Silicon Motion Technology (SIMO) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades, Hot Downgrades
Related EntitiesCredit Suisse, Robert Willoughby
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!